[1] |
IBA T,GANDO S,SAITOH D,et al.Efficacy and bleeding risk of antithrombin supplementation in patients with septic disseminated intravascular coagulation:a third survey[J]. Clin Appl Thromb Hemost,2017,23(5):422-428.
|
[2] |
于佳,陈淘江,王冬梅,等. 炎症因子、凝血指标和内皮细胞损伤标记物在恶性血液病脓毒症早期诊断中的应用?[J]. 肿瘤预防与治疗,2019,32(8):688-693.
|
[3] |
张宇,梁志锋,徐象辉. 犀角地黄汤联合西药对脓毒症凝血功能障碍患者临床疗效、凝血指标及预后的影响[J]. 中国医学创新,2019,16(16):116-119.
|
[4] |
SINGER M,DEUTSCHMAN C S,SEYMOUR C W,et al.The third international consensus definitions for sepsis and septic shock(Sepsis-3)[J]. JAMA,2016,315(8):801-810.
|
[5] |
宋辉,孔飞飞,刘旋,等. 网织血小板及其相关参数在儿童免疫性血小板减少症及脓毒症中的应用[J]. 检验医学,2018,33(7):626-628
|
[6] |
王建立. β受体阻滞剂治疗脓毒症相关心功能不全的临床疗效及预后分析[J]. 世界临床医学,2017,11(7):90.
|
[7] |
张志彪,严丽. PCT、LAC/ScvO2比值对脓毒症患者病情危重程度与预后的评估价值[J]. 临床急诊杂志,2019,20(2):119-123.
|
[8] |
KOWAL-VERN A,ORKIN B A.Antithrombin in the treatment of burn trauma[J]. World J Crit Care Med,2016,5(1):17-26.
|
[9] |
张翠. 微小RNA-132和高迁移率族蛋白1在脓毒症患儿外周血单个核细胞中的表达及临床意义[J]. 检验医学,2018,33(9):815-818.
|
[10] |
许志平,马红玲,陈双峰,等. MCP-1和mHLA-DR检测对脓毒症患者病情危重程度及预后评估的临床意义[J]. 中华重症医学电子杂志(网络版),2019,5(3):225-229.
|
[11] |
TANRIVERDI H,TOR M M,KART L,et al.Prognostic value of serum procalcitonin and C-reactive protein levels in critically ill patients who developed ventilator-associated pneumonia[J]. Ann Thorac Med,2015,10(2):137-142.
|
[12] |
MATSUMOTO S,SUDA K,IIMOTO S,et al.Prospective study of deep vein thrombosis in patients with spinal cord injury not receiving anticoagulant therapy[J]. Spinal Cord,2015,53(4):306-309.
|
[13] |
PRUCHA M,BELLINGAN G,ZAZULA R.Sepsis biomarkers[J]. Clin Chim Acta,2015,440:97-103.
|
[14] |
SINGH B,HANSON A C,ALHURANI R,et al.Trends in the incidence and outcomes of disseminated intravascular coagulation in critically ill patients(2004-2010):a population-based study[J]. Chest,2013,143(5):1235-1242.
|